checkAd

     179  0 Kommentare Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

    Relief Therapeutics Holding SA / Key word(s): Regulatory Admission
    Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

    28-Jul-2022 / 07:00 CET/CEST
    Release of an ad hoc announcement pursuant to Art. 53 LR
    The issuer is solely responsible for the content of this announcement.


     

    Acer Therapeutics amd Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

    Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023

     NEWTON, MA and GENEVA, SWITZERLAND – July 28, 2022 – Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the U.S. Food and Drug Administration (FDA) has accepted for review Acer’s resubmitted New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs). The FDA designated the NDA as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2023.

    “We are very pleased to receive confirmation that the FDA is commencing its review of our NDA resubmission,” said Chris Schelling, Founder & Chief Executive Officer of Acer. “We have notified the FDA that our third-party contract packaging manufacturer is ready for inspection and are hopeful that the Agency’s review can be completed in a timely manner. While NDA approval is not assured, if approval is received, we are prepared to execute on our comprehensive launch plan and provide a new treatment option to underserved UCDs patients. These efforts reinforce our ongoing commitment to developing new and differentiated treatment options for those affected by rare diseases.”

    In June 2022, as previously announced, the FDA issued Acer a Complete Response Letter (CRL) stating that satisfactory inspection of Acer’s third-party contract packaging manufacturer is required before the ACER-001 NDA may be approved. Acer notified the FDA in the NDA resubmission that the third-party contract packaging manufacturer is ready for inspection. The FDA did not cite any other approvability issues in the CRL pertaining to the NDA, nor request any additional clinical or pharmacokinetic studies be conducted prior to FDA action. Additional existing nonclinical information as requested by the FDA in the CRL but identified as “not an approvability issue”, as well as labeling and other required updates to the original NDA, were provided in the resubmission of the NDA. 

    Seite 1 von 5



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs 28-Jul-2022 / 07:00 CET/CEST Release of an ad …